ArticleClinical investigation2011
miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma.
Article in Clinical investigation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Epigenetics and Metabolism Reprogramming Interplay into Glioblastoma: Novel Insights on Immunosuppressive Mechanisms.Antioxidants (Basel, Switzerland) · 2023Review
- Immune Modulatory Short Noncoding RNAs Targeting the Glioblastoma Microenvironment.Frontiers in oncology · 2021Review
- Novel Role of miR-18a-5p and Galanin in Rat Lung Ischemia Reperfusion-Mediated Response.Oxidative medicine and cellular longevity · 2021Article
- Non-coding RNAs in Brain Tumors, the Contribution of lncRNAs, circRNAs, and snoRNAs to Cancer Development-Their Diagnostic and Therapeutic Potential.International journal of molecular sciences · 2020Review
- Regulatory effects of miRNA on gastric cancer cells.Oncology letters · 2014Article
- NF-κB-modulated miR-130a targets TNF-α in cervical cancer cells.Journal of translational medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Glioblastoma (GB), the most common primary neoplasm of the CNS, remains universally fatal with standard therapies and has a mean overall survival time of only 14.6 months. Even in the most favorable situations most patients do not survive longer than 2 years. Another hallmark of GBs, apart from the poor control of proliferation, is an immune suppressed tumor microenvironment. miRNAs usually bind the 3' untranslated region of target mRNAs and direct their post-transcriptional repression. Certain miRNAs are known to have altered expression levels in GB tumors, and in many immune cell subtypes. miRNAs have been found to serve important roles in gene regulation and are implicated in many processes in oncogenesis and immune deregulation. In this article we focus on the miRNAs involved in gliomagenesis and in the regulation of the immune response. We also present current challenges and miRNA immunotherapeutic strategies that should be investigated further.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.